Skip to content
- Hartmann JT, et al. Tyrosine kinase inhibitors – a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10(5):470-81.
- Keisner SV, et al. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011;71(4):443-54.
- Motzer RJ, et al. (the RECORD-1 study group). Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised placebo-controlled phase III trial. Lancet 2008;372:449-56.
- Schutz FA, et al. Hematologic toxicities in cancer patients with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. Crit Rev Oncol Hematol 2011 (Epub ahead of print).